Market Overview

Top 4 Mid-Cap Stocks In The Drugs-Generic Industry With The Highest ROA

Related AKRX
UPDATE: CRT Capital Upgrades Akorn
Meet The 5 Companies Loving Obamacare
Merck Sells Japan Eye-Treatment Rights (Fox Business)
Related SLXP
How Adam Feuerstein Follows The Biotech Sector
Deutsche Bank Slashes Price Target On Salix Pharmaceuticals
Making Money With Charles Payne: 10/17/14 (Fox Business)

Below are the top mid-cap drugs-generic stocks on the NYSE and the NASDAQ in terms of return on assets.

The trailing-twelve-month return on assets at Akorn (NASDAQ: AKRX) is 13.00%. Akorn's EPS for the same period is $0.46.

The trailing-twelve-month return on assets at Salix Pharmaceuticals (NASDAQ: SLXP) is 6.40%. Salix's revenue for the same period is $1.12 billion.

The trailing-twelve-month return on assets at Mallinckrodt plc (NYSE: MNK) is 2.50%. Mallinckrodt's operating margin for the same period is 9.20%.

The trailing-twelve-month return on assets at Hospira (NYSE: HSP) is 1.00%. Hospira's PEG ratio is 5.78.

Posted-In: Drugs-Generic Industry Mid-Cap ROATrading Ideas

 

Related Articles (AKRX + HSP)

Around the Web, We're Loving...

Get Benzinga's Newsletters